Nov 08,2022

Senseonics Holdings, Inc. Reports Third Quarter 2022 Financial Results

Senseonics Holdings today reported financial results for the quarter ended September 30, 2022. Total revenue for the third quarter of 2022 was $4.6 million, compared to $3.5 million for the third quarter of 2021. U.S. revenue was $1.9 million in the third quarter of 2022, compared to $0.6 million in the prior year period, and revenue outside the U.S. was $2.7 million in the third quarter of 2022, compared to $2.9 million in the prior year period.

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 09,2022

Senseonics to Present at the Stifel 2022 Healthcare Conference

Management is scheduled to participate on Tuesday, November 15, 2022 at 11:30am ET and will hold one-on-one meetings following.

CONFERENCES

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 10,2022

New IDTechEx Report Forecasts US$27Bn in 2033 for Electronic Skin Patches Market

IDTechEx have published their latest research, "Electronic Skin Patches 2023-2033", which estimates that the electronic skin patch market will grow to over US$27bn by 2033. In diabetes and heart monitoring, electronic skin patches have already transformed the industry. These devices may well enable a revolution for the rest of healthcare and beyond.

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 14,2022

Dexcom Invites the Diabetes Community to #seediabetes This November and Share Their Diabetes Story With Custom Continuous Glucose Monitor (CGM) Patches

DexCom, its global partners and Dexcom Warriors will once again help the world #SeeDiabetes and empower members of the diabetes community to express their unique journey with diabetes in an accessible way – by creating custom Dexcom CGM patches via the newly launched design site that illustrate just how unique each person’s diabetes story is.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 16,2022

Abbott FreeStyle LibreLink app now pairs with Novo Nordisk insulin pens in UK

Novo Nordisk announced that users of the Abbott FreeStyle LibreLink app can connect to its smart insulin pens. People living with diabetes in the United Kingdom can connect the app to the Novo Nordisk smart, connected pens. Users of the Abbott FreeStyle LibreLink app with FreeStyle Libre glucose sensing technology can see a range of information related to their diabetes. This includes dose timing and the amount of insulin taken, plus how those metrics impact their individual glucose patterns.

COLLABORATION PARTNERSHIP

#connected device

#insulin pen

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 28,2022

Ypsomed, CamDiab launch first automated insulin dosing system with Abbott FreeStyle Libre 3

The Ypsomed mylife YpsoPump combines with the CamDiab mylife CamAPS FX algorithm and FreeStyle Libre 3. Together, they form an intelligent and automated insulin delivery (AID) system for people with type 1 diabetes. Users can better control glucose levels and alleviate the burden of daily diabetes management.

PRODUCT

#insulin pump

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 30,2022

Q&A: How Carbon Health plans to modernize 'disconnected' chronic care

In 2021, omnichannel healthcare provider Carbon Health acquired Steady Health, an integrated diabetes care platform, and earlier this year launched its own management program. Myoung Cha, chief strategy officer at Carbon Health, spoke with MobiHealthNews via email to discuss the program's results, how his previous experience at Apple influences his decisions, and how combining in-person care and technology will drive Carbon Health's platform in the future.

#virtual care

#mobile app

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 18,2022

Medtronic leverages data science to launch first-of-its-kind personalized insights program for people living with diabetes

Medtronic is introducing a new program called My Insights exclusively made for individuals using the MiniMed™ 770G system. Using an individual's data, My Insights relies on the power of data science to provide personalized tips, trends, and reminders that customers can use to help with their diabetes management goals. The My Insights personalized recommendations are shared via a monthly email with educational content that is most relevant based on what an individual may currently be experiencing.

PRODUCT

#cgm

#closed loop

#mobile app

View Analyst & Ambassador Comments
Go to original news
Oct 19,2022

Abbott beats The Street in Q3 on stronger medical device sales

Abbott (NYSE: ABT) today reported third-quarter results that beat the consensus forecast on Wall Street, upping its full-year EPS guidance. Investors, however, seemed to react negatively to the company’s year-over-year decline in earnings and sales in Q3. Abbott earned $1.4 billion, or 81¢ per share, off $10.4 billion in revenue for the quarter ended Sept. 30, 2022, for a bottom-line slide of nearly 32% and a top-line cut of 4.7% compared with Q3 2021.

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 24,2022

Development of automated insulin delivery systems simplifies diabetes management

Automated insulin delivery (AID) systems, or hybrid closed-loop systems, have been developed to make the job easier. Such systems allow for a complete circle of communication between a continuous glucose monitor (CGM) and insulin pump, which tracks blood glucose and automatically adjusts insulin delivery to help control blood glucose levels. According to GlobalData analysis, the CGM and insulin pumps market was valued at $10.7bn last year. It is expected to reach $20.2bn in 2030, with a compound annual growth rate (CAGR) of 7.3% from 2021 to 2030.

#insulin pump

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM